» Articles » PMID: 33641009

Heterogeneity in α-synuclein Fibril Activity Correlates to Disease Phenotypes in Lewy Body Dementia

Overview
Specialty Neurology
Date 2021 Feb 28
PMID 33641009
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

α-Synuclein aggregation underlies pathological changes in Lewy body dementia. Recent studies highlight structural variabilities associated with α-synuclein aggregates in patient populations. Here, we develop a quantitative real-time quaking-induced conversion (qRT-QuIC) assay to measure permissive α-synuclein fibril-templating activity in tissues and cerebrospinal fluid (CSF). The assay is anchored through reference panels of stabilized ultra-short fibril particles. In humanized α-synuclein transgenic mice, qRT-QuIC identifies differential levels of fibril activity across the brain months before the deposition of phosphorylated α-synuclein in susceptible neurons. α-Synuclein fibril activity in cortical brain extracts from dementia with Lewy bodies (DLB) correlates with activity in matched ventricular CSF. Elevated α-synuclein fibril activity in CSF corresponds to reduced survival in DLB. α-Synuclein fibril particles amplified from cases with high fibril activity show superior templating in the formation of new inclusions in neurons relative to the same number of fibril particles amplified from DLB cases with low fibril activity. Our results highlight a previously unknown broad heterogeneity of fibril-templating activities in DLB that may contribute to disease phenotypes. We predict that quantitative assessments of fibril activities in CSF that correlate to fibril activities in brain tissue will help stratify patient populations as well as measure therapeutic responses to facilitate the development of α-synuclein-targeted therapeutics.

Citing Articles

Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases.

Sokratian A, Zhou Y, Tatli M, Burbidge K, Xu E, Viverette E Sci Adv. 2024; 10(44):eadq3539.

PMID: 39485845 PMC: 11800946. DOI: 10.1126/sciadv.adq3539.


α-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with Lewy body disease.

Kurihara M, Satoh K, Shimasaki R, Hatano K, Ohse K, Taira K NPJ Parkinsons Dis. 2024; 10(1):190.

PMID: 39433540 PMC: 11494045. DOI: 10.1038/s41531-024-00806-y.


Self-limiting multimerization of α-synuclein on membrane and its implication in Parkinson's diseases.

Ma D, Zhang S, Xu S, Huang Z, Tao Y, Chen F Sci Adv. 2024; 10(41):eado4893.

PMID: 39383232 PMC: 11463274. DOI: 10.1126/sciadv.ado4893.


Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays.

Srivastava A, Wang Q, Orru C, Fernandez M, Compta Y, Ghetti B PLoS Pathog. 2024; 20(9):e1012554.

PMID: 39302978 PMC: 11451978. DOI: 10.1371/journal.ppat.1012554.


Evidence for S-G-S-L within the amyloid core of myocilin olfactomedin domain fibrils based on low-resolution 3D solid-state NMR spectra.

Saccuzzo E, Robang A, Gao Y, Chen B, Lieberman R, Paravastu A bioRxiv. 2024; .

PMID: 39149386 PMC: 11326258. DOI: 10.1101/2024.08.09.606901.


References
1.
Polinski N, Volpicelli-Daley L, Sortwell C, Luk K, Cremades N, Gottler L . Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. J Parkinsons Dis. 2018; 8(2):303-322. PMC: 6004926. DOI: 10.3233/JPD-171248. View

2.
Nelson P, Jicha G, Kryscio R, Abner E, Schmitt F, Cooper G . Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2009; 257(3):359-66. PMC: 2839040. DOI: 10.1007/s00415-009-5324-y. View

3.
Smith J, Knowles T, Dobson C, MacPhee C, Welland M . Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad Sci U S A. 2006; 103(43):15806-11. PMC: 1635084. DOI: 10.1073/pnas.0604035103. View

4.
Chen G, Xu T, Yan Y, Zhou Y, Jiang Y, Melcher K . Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017; 38(9):1205-1235. PMC: 5589967. DOI: 10.1038/aps.2017.28. View

5.
Tarutani A, Arai T, Murayama S, Hisanaga S, Hasegawa M . Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. Acta Neuropathol Commun. 2018; 6(1):29. PMC: 5907316. DOI: 10.1186/s40478-018-0532-2. View